Trial · NCT00277355

Pilot Study of Minocycline in Huntington's Disease

NCT00277355, Phase 2, Phase 3, Completed, Merit Cudkowicz; results first posted 2013-04-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pilot Study of Minocycline in Huntington's Disease. Trials, record NCT00277355. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00277355

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pilot Study of Minocycline in Huntington's Disease
NCT number: NCT00277355
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 114 participants, actual
Lead sponsor: Merit Cudkowicz
Conditions: Huntington Disease
Interventions: minocycline, Matching placebo
First posted: 2006-01-16
Last updated: 2013-04-19
Results first posted: 2013-04-19

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]	Baseline to 18 months	Establish preliminary estimate of minocycline's impact on progression of HD (measured by the change in Total Functional Capacity (TFC) score of Unified Huntington's Disease Rating Scale \[UHDRS\] between baseline \& Month 18), and to assess futility of further study of minocycline. TFC consists of five ordinally scaled items assessing a person's capacity with: 1. occupation 2. financial affairs 3. domestic responsibilities 4. activities of daily living and 5. independent living. Total score ranges from zero (worst) to 13 (best).
Secondary	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]	Baseline to 18 months	TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). Regression based imputation was used to impute missing values.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]	Baseline to 18 months	The primary analyses were performed according to the intent to treat principle and included all randomized subjects. Two strategies were used to address missing data: 1. Last observation carried forward (LOCF) was used to impute missing values and 2. A secondary method of regression-based multiple imputation was also used.	units on a scale	MEAN
SECONDARY	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]	Baseline to 18 months	The primary analyses were performed according to the intent to treat principle and included all randomized subjects. Two strategies were used to address missing data: 1. Last observation carried forward (LOCF) was used to impute missing values and 2. A secondary method of regression-based multiple imputation was also used.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]	Minocycline 100 mg Twice Daily	1.55	Standard Deviation 1.85	units on a scale
Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]	Matching Placebo Twice Daily	1.15	Standard Deviation 1.70	units on a scale
Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]	Minocycline 100 mg Twice Daily	1.71	Standard Deviation 1.96	units on a scale
Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]	Matching Placebo Twice Daily	1.15	Standard Deviation 1.70	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Minocycline 100 mg Twice Daily	87
Overall Study	STARTED	Matching Placebo Twice Daily	27
Overall Study	COMPLETED	Minocycline 100 mg Twice Daily	73
Overall Study	COMPLETED	Matching Placebo Twice Daily	22
Overall Study	NOT COMPLETED	Minocycline 100 mg Twice Daily	14
Overall Study	NOT COMPLETED	Matching Placebo Twice Daily	5

Source ClinicalTrials.gov

Adverse events92

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dysphagia	Gastrointestinal disorders	Minocycline 100 mg Twice Daily	4	87
other	Dysphagia	Gastrointestinal disorders	Matching Placebo Twice Daily	2	27
other	Nausea	Gastrointestinal disorders	Minocycline 100 mg Twice Daily	7	87
other	Nausea	Gastrointestinal disorders	Matching Placebo Twice Daily	0	27
other	Irritability	General disorders	Minocycline 100 mg Twice Daily	5	87
other	Irritability	General disorders	Matching Placebo Twice Daily	1	27
other	Bronchitis	Infections and infestations	Minocycline 100 mg Twice Daily	0	87
other	Bronchitis	Infections and infestations	Matching Placebo Twice Daily	2	27
other	Gatrointestional viral	Infections and infestations	Minocycline 100 mg Twice Daily	2	87
other	Gatrointestional viral	Infections and infestations	Matching Placebo Twice Daily	2	27

1 to 10 of 92Source ClinicalTrials.gov

See all 92 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Minocycline 100 mg Twice Daily
Total, all-cause mortality	Matching Placebo Twice Daily
Total, other adverse events	Minocycline 100 mg Twice Daily	74	87
Total, other adverse events	Matching Placebo Twice Daily	23	27
Total, serious adverse events	Minocycline 100 mg Twice Daily	11	87
Total, serious adverse events	Matching Placebo Twice Daily	1	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
15304592	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Minocycline 100 mg Twice Daily vs Matching Placebo Twice Daily: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00277355

GET https://conductscience.org/api/trials/v1/NCT00277355/events?page=2

API reference For AI assistants